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ABSTRACT

While there is evidence for a decline in olfactory identification scores for patients with
Kidney Disease, there are contradictory results for detection thresholds. Some results indicate
higher thresholds while others found similar thresholds or elevated thresholds for one odorant,
but not others. The current study evaluated the olfactory abilities with participants diagnosed
with Kidney Disease for numerous odorants. No significant differences were found in olfactory
identification, detection thresholds, or sensitivity compared to healthy controls. Despite the nonsignificant results, there did appear a trend of poorer olfactory abilities in Kidney Disease
participants. The differences in olfactory performance also varied from odorant to odorant which
indicates that a standardized set of odorants should be used when assessing threshold detection
scores in the Kidney Disease population.
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CHAPTER I
INTRODUCTION

Our olfactory abilities are a sense that most of us take for granted. At one point, our sense
of smell was actually classified as a “lower” or “minor” sense (Blake & Sekuler, 2005). Such
little attention is paid to the olfactory abilities that some individuals are not even aware that they
lost their ability to smell (Landis, Hummel, Hugentobler, Giger, & Lacroix, 2003).
Unfortunately, most people do not realize the importance of a normal sense of smell or that
deficits in olfactory abilities can lead to issues in nutrition, quality of life, and psychological
well-being (Doty, 2006).
Furthermore, most people are not educated in the various applications of olfactory
functioning assessment. Assessments of olfactory abilities can allow for early detections of
diseases and disorders as well as assist in differential diagnoses (Haehner, Hummel, &
Reichmann, 2011; Rahayel, Frasnelli, & Joubert, 2012; Solomon, Petrie, Hart, & Brackin Jr,
1998). Fortunately there has been an increase in the availability of olfactory tests for clinicians
(Doty, 2006). These tests can be used to assess a wide variety of olfactory performance.
There are several different assessments that can be used to measure olfactory abilities.
Some of the more popular assessments are: Olfactory Identification (OI), Detection Thresholds
(DT), Sensitivity, Odorant Discrimination, and Memory Tasks. For the purpose of this study,
only OI, DT, and Sensitivity are discussed.
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One disease that is associated with of olfactory decline is Kidney Disease (KD),
specifically, Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). CKD is
characterized by having kidney damage for three months or more. The disease can be broken into
five stages (1-5), with a decrease in filtration rates from one stage to the next. Stage 5 of CKD
and ESRD are both described as kidney failure, but differ in that ESRD requires chronic kidney
dialysis (Bronnert, 2007). The incidence and prevalence of CKD has increased by 30% (Hallan
& Vikse, 2008) and as of 2005, there were an estimated 1.9 million people suffering from ESRD
(Grassmann, Gioberge, Moeller, & Brown, 2006). Like most illnesses, treatment can be very
expensive which may deter people from seeking treatment and lead to prolonged symptoms
(Hallan & Vikse, 2008).
Frasnelli, Temmel, Quint, Oberbauer, and Hummel (2002) found that 56% of the patients
in chronic renal failure had olfactory deficits. This becomes a serious issue given the impact
olfactory abilities can have on quality of life and appreciation for food (Griep et al., 1997).
Specifically, it was found that renal patients with the greatest olfactory dysfunction also are the
most likely to become malnourished (Raff et al., 2008).
While there is an association of olfactory deficits with KD, there is conflicting data.
Some research indicates that those suffering from renal problems actually have normal olfactory
functioning (Vreman, Venter, Leegwater, Oliver, & Weiner, 1980) while others depict some type
of olfactory deficit (Griep et al., 1997). These results may actually be a result of the methods
used to assess olfaction or a result of other symptoms associated with the disease.
There are variables other than diseases that can affect our sense of smell. Age and Gender
are two of the more commonly known. There is a long history of anecdotal evidence suggesting
that females are better smellers. More recently a significant amount of research has been
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conducted to justify those claims (Good & Kopala, 2006). Moreover, certain physical and mental
disorders can affect olfactory performance. In the CKD and ESRD population, for example, there
is an increased risk of sleep disorders (Kimmel, Miller, & Mendelson, 1989; Pierratos & Hanly,
2011). Depression is the most common psychiatric disorder in this population (Kimmel &
Peterson, 2004; Kimmel, Weihs, & Peterson, 1993). These disorders will be discussed in the
current study in the context of declines in olfactory performance with kidney disease.

Olfactory Measures
Since the mid to late 1980s, the number of easily administered measures for assessing
olfaction has increased (Doty, 2006). These measures became generally available during the
2000s (Doty, 2009). In addition, they allow for reliable measures of olfactory tasks and have
many applications (Doty, 2006). It should be noted that most olfactory measures correlate
positively with one another, but DTs correlate negatively with OI tasks (Doty, 2009). This
negative correlation occurs because as one’s threshold increases, there is a decrease in the ability
to detect odorants. This increased threshold accounts for the decrease in scores on OI tasks.

Odorant Identification
The assessment of OI has proven to be very reliable and has helped shape the current
knowledge of human olfaction (Doty, 2006). A common way for measuring a person’s ability to
identify an odorant is through the use of a microencapsulated odorant, or “scratch ‘n’ sniff” card
(Blake & Sekuler, 2005). The University of Pennsylvania Smell Identification Test (Doty,
Shaman, & Dann, 1984), a 40-item multiple forced choice smell test, is arguably the most
popular and widely used assessment of OI (Doty, 2009). This test is administered by having a
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participant scratch the surface of a “scratch and sniff” card, smell the odorant, and then decide
which smell on a list of choices best represents the odorant. Even if the participant does not
detect an odorant, or the choices provided do not match what the participant believes the odorant
to be, a choice from the list must still be selected (Doty, 1995), which is referred to as a forcedchoice test. This test has been shown to be sensitive enough to distinguish variances in gender,
smokers vs. nonsmokers, and ethnic groups (Doty et al., 1984).
Smell identification tests have been proven to be reliable. These tests can actually have
only three questions and still have relatively high reliability and sensitivity (Duff, McCaffrey, &
Solomon, 2002). Reliability coefficients have been shown to be > .7 for multiple measures
(Doty, Newhouse, & Azzalina, 1985). However, there is a positive relationship of reliability with
the length of the test (Doty, 2006; Doty, Frye, & Agrawal, 1989). This relationship may occur as
a result of the decreased probability of correctly guessing multiple odorants.
Given the sensitivity and reliability of the OI test, it has been used for diagnosing
purposes. Solomon et al. (1998) were able to distinguish participants by either major depression
or Alzheimer’s Disease (AD). The researchers discovered that the AD group performed
significantly worse than the depressed group. Using similar methods, an olfactory measure was
again used as a diagnostic tool to distinguish AD from vascular dementia (Duff et al., 2002).

Detection Threshold
The minimum amount of a stimulus (odorant, sound, light, etc.) needed in order to be
detected is referred to as the DT (Møller, 2003). There are currently several methods for
threshold task administration, but all present olfactory tasks follow the Ascending Method of
Limits (AML) or Single Staircase (SS) methods (Doty, 2009). The AML procedure presents an
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odorant at various levels, first with the lowest dilution presented followed by the next higher
dilution and so forth. Two successive odorant detections determine the threshold. Other threshold
tasks follow the same procedure, but then present the odorant dilutions in a descending fashion
(thresholds determined from two successive non-detections) and average the two obtained
thresholds (Doty, 2006).
The SS procedure follows a similar basis as AML; except the dilutions are increased with
a no detection response and dilutions are decreased with a detection response. After five
reversals, the stimuli where the reversals occurred are averaged to obtain the threshold (Doty,
2009). The more popular version of threshold tasks uses the staircase method and adds blanks (a
stimulus that contains no odorant, also referred to as noise). Instead of presenting the blanks at a
separate time, the blanks are presented with the odorant (again with various dilutions) and the
participant is asked to pick (forced choice response similar to OI) which one contains the odorant
(Doty, 2009; Landis et al., 2011). The reversals are dependent on whether or not the response
was correct (dilutions increase with incorrect response and vice versa). The advantage of adding
blanks is the control provided from those who may guess. For example, Suzuki et al. (2001) used
a similar method to determine olfactory thresholds by increasing the dilution after an incorrect
response, and then repeating the same stimuli after a correct response. After 5 correct responses,
the dilution in the presented stimuli becomes the threshold.
Unfortunately, there are limitations to the current methods of DTs, especially in
reliability and validity (Doty, 2009). Doty (2006, 2009) recommends using a SS procedure for
measuring DTs because of the increased reliability and stability. This increase is obtained by
using reversals and presenting certain stimuli multiple times; more trials increase reliability and
stability. However, this method still does not allow for every stimulus to be presented multiple
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times. The stimuli presented are dependent on the participant’s responses. The location of
reversals may be within a specific range which would never allow the participant to be presented
the extended range of concentrations. To alleviate these problems, a new threshold test was
developed to better align with other perceptual threshold tasks measuring vision and audition.
The new measure created for obtaining olfactory DTs is called The Wheeler University
of Tennessee at Chattanooga (WUTC) Threshold Test (Tewalt, 2013). The WUTC consists of
not one, but five odorants and blanks. Vanillin, L-α-Pinene, Ethanol, Isoamyl Acetate (Banana),
and P-cresol. P-cresol, a uremic toxin found in ESRD patients (Lin et al., 2011; Meijers et al.,
2010) with an odorant characterized as pig manure (Le, Aarnink, Ogink, Becker, & Verstegen,
2005), was chosen to see if a build-up of this toxin in the blood system would affect the ability to
detect the odorant. McKinney (2013) showed that there is no presence of P-cresol in the healthy
population. Vanillin was chosen as it has a similar chemical structure to P-cresol. Banana has a
chemical structure that is different from Vanillin, yet it has a similar sweet smell. L- α-Pinene
and Ethanol do not have a sweet smell like Vanillin and Banana. None of the above odorants
overstimulate the fifth trigeminal nerve (the cranial nerve that supplies somatic nerves to the
nose). Stimulation of this nerve could cause a warm, sharp, or cool sensation (Hawkes & Doty,
2009).
The WUTC uses a slightly different method for obtaining the threshold through the use of
the Method of Constant Stimuli (MCS) and Signal Detection Theory (SDT). While this
methodology does differ slightly from existing methods used currently in detecting thresholds,
SDT is broadly accepted by psychologists and is applied whenever two possible stimuli need to
be discriminated from one another, or a stimulus needs to be detected, (Stanislaw & Todorov,
1999). The methods discussed above are concerned with whether or not a participant detects an
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odorant when the odorant is actually present although it is possible for a participant to say a
stimulus was detected when in fact nothing was actually there. SDT was adapted to overcome
this shortfall and accomplishes this through the use of “hits” and “false alarms” (Levine, 2000).
The hit rate (H) is calculated by taking the proportion of “yes” responses to signal stimuli and the
false alarm rate (F) is calculated by the proportion of “yes” responses to the blanks.
As stated earlier, the SS method incorporates blanks where a participant has to
distinguish between the stimuli and the blank. The difference in the methodology comes from the
requirement of MCS to have the test present the stimuli multiple times in a random order (Blake
& Sekuler, 2005). Note the SS procedure is not completely random, but instead relies upon the
participant’s response (a correct or incorrect response dictates what will be presented next) and
some individuals’ responses can generate shorter tests. When using AML or SS, it was actually
possible for the participant to figure out what intensity to expect next. The MCS was specifically
developed in order to alleviate these problems (Levine, 2000)
The WUTC uses nine different dilutions for each odorant and nine blank stimuli. Each
stimulus (both odorants and blanks) is presented one at a time to the participant in a random
order twice, in which he or she is asked to respond with a “yes” or “no” as to whether or not an
odorant was detected (Tewalt, 2013). A “yes” or “no” response is given for each presentation. By
creating the dichotomous response from the participant for both the odorants and blanks, further
methods can be used to assess other performance factors covered through SDT (Møller, 2003).
In order to determine the thresholds for the various odorants, the yes/no responses to the
odorant containing stimuli were analyzed using Logistic Regression. Through the Logistic
Regression analysis, estimated probabilities are obtained for each concentration of an odorant.
By graphing the relationship of the logarithmic concentration and probabilities with a sigmoid
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curve, the concentration associated with a probability value of .5 becomes the estimated
threshold (Tewalt, 2013). This method is identical to the general means of assessing auditory
thresholds (Møller, 2003). See Figure 1.1 below for a graphical representation of obtaining the
estimated threshold.

Figure 1.1

Individual’s Predicted Probability vs. Vanillin Concentration
The horizontal scale is graphed using a logarithmic scale to avoid skewness. Each point on the
graph represents the probability of that concentration being detected with an ogival curve added.
The horizontal line depicts where the probability of .5 would intersect the probability curve. The
vertical line was placed in the intersection to find the concentration for the threshold. The text box
attached to the horizontal line depicts the threshold.

8

The logistic regression analysis also gives a B coefficient. This coefficient helps
determine the size and direction in the probability of detecting the observed concentrations
(Tabachnick & Fidell, 2013). In other words, the B coefficient indicates if the change in
probabilities is a very sudden and sharp or more shallow and gradual. Moreover, the sign of the
coefficient allows for any detection in response confusion and guessing. The B coefficients help
identify any response confusion and determine if a change in concentrations for one odorant
seems to have more of an impact than others odorants.
In addition to using a more reliable method for obtaining thresholds, the WUTC
incorporates the use of blanks (but not in the fashion that blanks are used with the SS method).
Instead, the blanks are individually presented randomly with all of the other odorant containing
stimuli. This allows is for the participant to respond with a “yes” or “no” to the blanks
themselves and can be used for manipulation checks. As stated earlier, the previous methods
discussed force the participant to distinguish between an odorant containing stimuli and a blank.
This does not tell us if the participant detected something in the blank (it is possible the
participant thought they detected an odorant in both stimuli and guessed). The reason this new
addition of a response to a blank is important because it also allows for further calculations to be
made for Sensitivity through SDT.

Sensitivity
Additional measures of olfactory performance can be assessed by using SDT in the
WUTC. Specifically, the incorporation of a dichotomous response to each individual blank in
addition to the odorants enables the WUTC to calculate sensitivity. Sensitivity is an individuals’
ability to discern a signal from noise (or an odorant from blanks) and can be calculated from hit
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and false alarm rates (Stanislaw & Todorov, 1999). Although there is literature on olfactory
sensitivity, it is actually being used interchangeably with DT. Specifically, most of this research
refers to sensitivity as the inverse of DT. It may be counterintuitive to think of higher DT as
poorer performance, so some researchers refer to thresholds as sensitivity.
One method of calculating sensitivity is d’ (Miller, 1996). Sensitivity using d’ is
calculated by obtaining the z scores for the hit and false alarm rates, and then subtracting the
false alarm z score from the hit rate z score (Macmillan, 1993). This statistic can be affected by
response bias which is the tendency for a participant to respond with “yes” or “no” which is why
some researchers prefer a non-parametric measure of Sensitivity (Stanislaw & Todorov, 1999).
Response bias can be computed through the nonparametric statistic Grier’s B’’ (Grier,
1971). Ranges for B’’ can range from -1 to +1, with negative numbers indicating a bias towards
responding with “yes” and a bias to responding with “no” indicated by positive numbers. The
further away from 0 B’’ is, the greater the response bias. It seems counterintuitive to think of yes
with a negative affect, so the present study will multiply a -1 to B’’ in order to flip the signs,
resulting in positive numbers indicating a response bias of yes. The modified formula from
(Stanislaw & Todorov, 1999) is as follows:

(

(

))

( (
(

)
)

(
(

))
)

Eq. 1.1

Note: H = Hit Rate and F = False Alarm Rate
“sign(F – H)” equals +1 when F > H, 0 when F = H, and -1when F < H.

By calculating response bias, it will allow for a determination of DT being skewed as a result
response bias.
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Given that d’ can be affected by response bias; A’, a non-parametric statistic of sensitivity
(Macmillan, 1993) is used. The formula for calculating A’ is as follows (Stanislaw & Todorov,
1999):
[

(

)

(

)
(

|
)

|

]

Eq. 1.2

Note: H = Hit Rate and F = False Alarm Rate
“max(H,F)” indicates using which ever value is larger.

The ranges of A’ typically range from .5 – 1, with a value of .5 depicting no ability to distinguish
stimuli from blanks. It should also be noted that absolute lowest possible value of A’ is 0, but
any value lower than .5 is generally a result of error in sampling or response confusion
(Stanislaw & Todorov, 1999).
Sensitivity can be calculated for the entire test as well as for each individual odorant. This
will give the test the ability to analyze if there are varying performances between the odorants for
individual participants. This analysis is important because olfactory performance can vary
between odorants (Good & Kopala, 2006). For example, Landis et al. (2011) found that when
compared to healthy individuals, KD participants had elevated thresholds for one odorant, but
normal thresholds in a different odorant. These multiple calculations for the entire WUTC and
each individual odorant will help discern which specific odorants may be influenced by specific
variables and which should be used when assessing the KD population.

Variables Affecting Olfaction
Individuals vary in olfactory abilities and sensitivity. Some people are able to detect the
faintest odorant from across the room while others struggle to find its source. There are several
11

variables affecting olfactory abilities, arguably the most notable being gender. As anecdotal
evidence and research suggest, women outperform males on almost every olfactory task, (Good
& Kopala, 2006).
Additionally, these gender effects can be made greater with age (Good & Kopala, 2006).
The proportion of olfactory problems in the general population increases from 1-2% in those
younger than 65 years of age to >50% in those older than 65 (Doty, 2006). While olfactory
abilities do generally decrease with age, the decrease in performance is different for males and
females. There is a decrease in OI abilities as age of participant increases. As expected, female
performance is consistently greater than male performance, yet male performance begins to drop
further below female performance at 50-59. Female decline is not as steady as male decline
(Performance for both genders is similar at age 80-89, but females’ performance decreases less
gradually) (Doty et al., 1984). Similar effects from age were found in other studies for DTs
(Kobal et al., 2000). These differences in age may result from decreasing neurological activity
with increasing age (Suzuki et al., 2001).
While gender and age are common factors that affect olfactory abilities, other more
complex issues can also hinder olfactory abilities. Fortunately, if these deficits are discovered
early enough, they can be used to diagnosis underlying disease. For example, one of the earliest
symptoms of both AD and Parkinson’s Disease (PD) is an impaired olfactory sense (Haehner et
al., 2011; Rahayel et al., 2012). Olfactory tests have been used to be able to distinguish
neurodegenerative diseases from other disorders that generate difficult differential diagnoses
(Solomon et al., 1998). Even though there has been an increase in the number of easily
administered clinical smell tests for many noted medical conditions (i.e. AD, PD, Depression,
Sleep Disorders) (Doty, 2006), there has not been one developed for KD.
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Kidney Disease
One of the first studies to research olfaction in the KD population found that patients
showed poorer performance on odorant discrimination tasks and rated odorants as more
unpleasant when compared to healthy controls (Schiffman, Nash, & Dackis, 1978). Additionally,
Corwin (1989) found that renal patients on dialysis had poor OI abilities compared to healthy
controls. Raff et al. (2008) also found that participants diagnosed with ESRD had significantly
lower OI scores than controls and that these olfactory deficits can lead to serious health issues
like malnutrition (up to 75% of ESRD patients are malnourished) due to an inverse relationship
between nutrition scores and OI scores. This olfactory deficit is thought to be the cause of the
malnourishment (Landis et al., 2011).
Treatment for KD patients can actually improve olfactory function. Landis et al. (2011)
found after just one session of hemodialysis, OI performance was significantly improved.
However, this result is temporary and the KD patients suffer from long term consequences of
olfactory performance. If a patient receives a kidney transplant, his or her olfactory function
returns to levels similar to the healthy population (Griep et al., 1997). Unfortunately, like any
transplant, this treatment is complex and costly. However, the mechanisms responsible for these
recoveries in olfactory performance are still unknown (Landis et al., 2011).
While there is evidence for a decline in OI scores for patients in renal failure, there are
contradictory results for DTs. These results vary greatly, both in the initial testing for
comparisons and when measuring for treatment effects. The initial comparisons show the disease
population to have either normal thresholds (Frasnelli et al., 2002; Vreman et al., 1980), have
elevated thresholds (Griep et al., 1997), varied thresholds or an elevated threshold for one
odorant but a normal one for another (Landis et al., 2011). Similarly, when looking for

13

improvements in olfaction after treatment, results show either no change in threshold (Griep et
al., 1997), an improvement for thresholds (Korytowska & Szmeja, 1993), or an improvement in
one odorant threshold but not a second odorant (Landis et al., 2011).
Studies have shown that KD is associated with increased risks for depression (O’Donnell
& Chung, 1997) and sleep disorders (Lüdemann, Zwernemann, & Lerchl, 2001; Unruh et al.,
2006). Each of these disorders also has associations with impaired olfactory performance, adding
more confusion to olfactory impairment in KD patients.
In addition to olfactory dysfunction, another symptom of renal failure is a significant
reduction in normal nocturnal melatonin levels compared to healthy controls (Parker, 2003). This
change may be the cause of the observation of day-night reversal in sleep patterns of dialysis
patients (Parker, Bliwise, Bailey, & Rye, 2003). Over 50% of ESRD patients have sleep apnea
(Kimmel et al., 1989; Unruh et al., 2006) compared to the 2-4% in the general population
(Pierratos & Hanly, 2011).
Olfactory function has been shown to decrease with disturbances in Rapid Eye
Movement (REM) sleep (Fantini, Postuma, Montplaisir, & Ferini-Strambi, 2006; Miyamoto et
al., 2009; Postuma, Gagnon, Vendette, Desjardins, & Montplaisir, 2011). Parker et al. (2003)
found that REM and total sleep time was reduced by up to 50% in ESRD patients. Moreover, it
has been shown that even one night’s sleep loss can impair olfactory performance (Killgore &
McBride, 2006). While all of these studies have only shown a decline in OI, Stiasny-Kolster et
al. (2005) found that those with REM sleep disorders to have significantly reduced olfactory
abilities for OI, DT, and discrimination tasks.
As stated earlier, depression is also very prevalent in the KD population. Depression has
actually been under diagnosed in the ESRD population, with only ~14% being diagnosed by a
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physician although reliable scales of depression depict 43% as having major depressive
symptoms (Lopes et al., 2004). Olfactory deficits have been found in depression, yet there are
some discrepancies in the literature (Pantelis & Brewer, 2006). As opposed to KD, there is
conflicting data regarding the OI abilities, not the DTs. Serby, Larson, and Kalkstein (1990)
found OI deficits in depressed patients while Amsterdam, Settle, Doty, Abelman, and Winokur
(1987) and Solomon et al. (1998) found no dysfunction in OI abilities. However, there is a clear
consensus of a negative relationship between depression and DTs (Negoias et al., 2010; Pause,
Miranda, Göder, Aldenhoff, & Ferstl, 2001; Pollatos et al., 2007).

The Present Study
The present study is a small part of a much larger and still ongoing project supported by
Dialysis Clinics, Inc. (DCI) (Tumlin, 2012). The study as a whole will investigate
neurotransmitter levels, the safety of a drug supplementation, sleeping patterns and habits,
quality of life, depression, blood and plasma analyses, and olfactory performance over a two
month time period for each participant. However, only the olfactory portion will be presented in
this work. The present study will address and clarify the discrepancy in the literature by
obtaining several measures of olfactory ability. Additionally, a new measure for assessing
olfactory DTs was used in order to improve on the current methodology and to validate its use.
Lastly, the relationship of additional variables that may be better predictors of olfactory
performance and KD was assessed.
The main objective of the present study is to address and clarify the discrepancy in the
literature. While there are discrepancies in the DT literature for the KD population, there does
appear to be a trend of poor OI performance. The first hypothesis is:
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H1: The Kidney Disease participants will have significantly lower
OI scores compared to the control subjects.
The methodology in the new olfaction threshold test (the WUTC) will allow for a more
reliable measure of olfactory DTs. Olfactory performance can vary based on different odorants,
and the discrepancies in the threshold literature may be a result of using an unreliable or
irrelevant odorants for the population. Basing the DT measure on scents relevant to the CKD and
ESRD population should also allow for a greater accountability of variances in detection
performance between different populations (i.e. ESRD/CKD and control subjects). This
increased test accuracy leads to the second hypothesis:
H2: The Kidney Disease participants will have significantly higher
threshold scores compared to the control subjects.
Through the use of SDT and the dichotomous response to every stimulus (including
blanks), it will be possible to obtain actual measures of sensitivity for subjects. Since KD is
associated with olfactory deficits, they should have a decreased ability to distinguish odorants
from blanks. Thus, the third hypothesis is:
H3: The Kidney Disease participants will have significantly lower
sensitivity scores compared to the control subjects.
In addition to the increased reliability from the methods used in the WUTC, the test was
specifically designed to test olfactory abilities in the CKD and ESRD population. This specificity
should allow for the test to be used as a diagnostic tool. The fourth hypothesis is:
H4: The measures of the WUTC will be able to distinguish those with Kidney Disease from the
controls subjects with high specificity and sensitivity.
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Also, given the high prevalence of disorders that also affect olfaction in the ESRD and
CKD population, analyses will be utilized to assess for any possible moderating relationship that
may account for the varying results. This analysis was conducted by adding covariates into
regression models to see if any significant predictors of olfactory performance emerged. The
specific covariates assessed are sleep quality and depression. These variables are important given
the high prevalence of these disorders in the KD population.
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CHAPTER II
METHODS

Participants
The recruitment of KD participants was supported by DCI and conducted through the
Southeastern Renal Research Institute (SERRI). Control Subjects were recruited through a
community sample to be age and gender matched to the KD participants. The inclusion and
exclusion criteria differed for the KD participants and control subjects who also went through
slightly different procedures.

Kidney Disease Participants
Inclusion criteria for the KD population were that participants be between 18 and 85
years old. Participants also had to be diagnosed with either CKD or ESRD and if undergoing
dialysis, duration had to be greater than 3 or more months. Participants could also not be on any
sleep medications. Participants were recruited from the Chattanooga, TN area. There were a total
of 15 participants recruited, with a total of 8 participants (1 female) completing all requirements
for participating. Mean age was 56.2 (SD = 11.9) and 75% were African American (n = 6). For a
full list of inclusion and exclusion criteria, see Appendix A. Demographic information for these
participants were obtained through medical records. Any individual involved in the collection of
this data received certifications in the protection of human rights as research participants.
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Control Participants
Control participants were recruited based on characteristics of the KD participants. After
completion of protocols from KD participants, control subjects were recruited from the same
geographical area to be age and gender matched. Of the 8 KD participants, only 5 (1 female)
controls were obtained. Mean age was 54.4 (SD = 11.8, not significantly different from KD
participants) and 20% (n = 1) were African American. Controls were also matched based on
ethnicity. The discrepancies in the numbers were a result of a KD participant being excluded
from the current study as a result of incomplete olfactory data. Demographic information for the
control subjects was obtained through a demographic questionnaire. The questionnaire asked
participants to indicate age, gender, ethnicity, occupation, etc. It also asked participants to
indicate any history of specific illnesses and medication use in order to further match the KD
participants (See Appendix B for the complete demographics).

Materials
Materials include: the University of Pennsylvania Smell Identification Test (UPSIT)
(Doty et al., 1984), the WUTC (Tewalt, 2013), the Center for Epidemiologic Studies Depression
– Revised Scale (CESD-R) (Eaton, Smith, Ybarra, Muntaner, & Tien, 2004), and the Pittsburg
Sleep Quality Index (PSQI) (Buysse, Reynolds III, Monk, Berman, & Kupfer, 1989). These
materials can be found in Appendices C, D, E, and F, respectively.

University of Pennsylvania Smell Identification Test
The UPSIT is a 40 item test consisting of four booklets. Each booklet contains 10
different odorants located on separate pages with 4 possible choices to choose from for each
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odorant. The participants were instructed to use the pencil provided to scratch and release an
odorant and try to identify the odorant by selecting one of the provided choices as per the
instruction manual (Doty, 1995). A forced choice test, for the test to be valid each item must be
answered. If the participant does not detect an odorant or the choices do not represent what the
participant believes the odorant to be, they must still pick one of the choices. Each test booklet
and its odorants were presented to each participant in the same order. The participant score was
based on the percentage of correct responses (See Appendix C for UPSIT Key).

Wheeler University of Tennessee at Chattanooga Threshold Test
The WUTC consists of 54 tubes with nine different dilutions for five odorants and
blanks. Each tube contains 10ml of the odorant dilution or blank. The presentation of the tubes is
double blind, requiring two people to administer the test. One person was responsible for
recording responses and handing the tubes based on a randomized sequence sheet to the
presenting researcher. See Appendix D for a picture of the test and an example sequence sheet.
The odorants are Vanillin, L-α-Pinene, Ethanol, Isoamyl Acetate (Banana), and P-cresol. The
dilutions are made so the middle dilution coincides with detection threshold norms and are a
clear liquid. The blanks contain 10ml of purified distilled water. The tubes are presented to each
individual in a completely random order and each tube is presented for a total of two times.
Responses of, “yes,” for being able to detect the odorant and, “no,” for not being able to detect
the odorant were recorded for each tube presentation. An analysis using Logistic Regression was
used to obtain the projected threshold for each participant. If any B coefficient is negative, then
threshold cannot be computed as a result of response confusion.

20

Measures of sensitivity were also obtained from the WUTC. Values for the nonparametric measure A’’ were obtained by taking the proportion of detections in all stimuli that
contained odorants and the proportion on “yes” responses to blanks. These values were then
calculated using equation 1.2 to obtain an overall sensitivity measure. Since values less than .5
indicate some type of response confusion or sampling error, any participant whose A’’ <.05 was
omitted from analyses. Moreover, measures of A’’ were also calculated for each individual
odorant.

Center for Epidemiologic Studies Depression – Revised Scale
In order to obtain depression scores, the CESD-R was used. It is designed to measure
depression based on the 4th edition of the Diagnostic Statistical Manual (DSM-IV) and has been
shown to have high reliability (Eaton et al., 2004). This measure consists of 20 items using a 4
point Likert scale (0-3) asking participants to rate his or her feelings during the past week. The
final depression scores is a summation of the 20 items resulting in a range of scores from 0 to 60.
A higher score indicates greater depression. Scores 16 and over are indicative of being clinically
depressed and is used as a diagnostic cut off. See Appendix E for the complete CESD-R.

Pittsburg Sleep Quality Index
The PSQI is a 19 item self-report measure for assessing sleep quality and disturbances in
the past month. Four of the items ask for open ended responses such, “How many hours of actual
sleep do you get at night?” The rest of the items are rated on a 4 point Likert Scale (0-3). The
open ended items were recoded into a 0-3 scale. These recodes were made according to the
scoring instructions. The PSQI is broken up into 7 components, each with instructions for
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scoring based on the responses from the 19 items. Scores can range from 0 to 21 with higher
scores indicating poor sleep. Scores 5 and higher are typically indicative of poor sleep. See
Appendix F for the full PSQI. Specific scoring instructions can be found through Buysse et al.
(1989).

Procedure
All data collected was managed and analyzed using the IBM Statistical Package for the
Social Sciences (SPSS). No personal identifying information was entered into these files, and all
data files were kept on an encrypted hard drive to further protect personal information. The
following procedures were approved by the Institutional Review Board (See Appendix G for the
Kidney Disease IRB Approval Letter and Appendix H for the Control IRB Approval Letter)

Kidney Disease Procedure
Upon giving consent for the larger study, KD participants were scheduled to come into a
research facility for a morning and afternoon appointment. If the participant was on dialysis, the
scheduled appointments fell on a non-dialysis days. During each of the times, protocols for the
blood analysis investigation which was part of the larger study would be implemented. After
completing this necessary aspect of the study which also included the PSQI, participants were
brought into a room and were given a battery of psychometric tests for this study which included
the CESD-R, UPSIT, and WUTC. Participants first completed the CESD-R. Detailed
instructions were given to each participant verbally, as well as having written instructions at the
top of every page. After completing the questionnaire packet, participants were given the first
booklet from the UPSIT. Verbal instructions were given based on the instructions attached with

22

the UPSIT. Subsequent booklets were given after completing the previous one. Lastly, the
WUTC was administered. Since the WUTC is a double blind administration, the participant was
seated facing away from the researchers. One researcher was responsible for presenting the tube
to the participant, while the other pulled tubes based on the randomized sequence sheet.
Participants were instructed that some of the tubes contained an odorant while others did not and
the ones that do contain odorants have varying amounts. Participants were then instructed they
had 3-5 seconds to smell the tube and to then respond with whether or not they detected an
odorant. After completing the WUTC, participants were free to leave.
Since the KD participants were also participating in the larger study, they were not
debriefed as to the nature of the study or given results of their performance. This was done to
prevent any future response bias in the follow up examinations when the procedure is replicated.

Control Subject Procedure
The protocol for the controls was matched as much as possible to the KD procedure.
After recruitment, participants were brought to a local university. Upon arriving, consent was
first obtained from participants (See Appendix I). Next, the controls took the same battery of
psychometric tests as the KD participants did with the addition of the demographic
questionnaire. The same verbal and written instructions were given for completing the
questionnaires and olfactory measures. When administering the WUTC, controls were set up in a
similar fashion as the KD participants.
The procedure differed for the controls in that they were debriefed about the purpose of
the study. There was no need to prevent any future response bias as controls participated in only
one session.
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Statistical Analyses
An independent samples t test was used to analyze the hypotheses regarding poorer
olfactory performance in the KD participants compared to the controls. The t test was also used
to compare age between the two groups. In order to obtain thresholds for each participant, a
logistic regression analysis was used. This analysis allowed for predicted probabilities to be
saved for each concentration. A graph was then created with the concentrations on the x-axis and
probabilities on the y-axis for each participant. An ogival curve was then plotted through points
on the graph and a horizontal line was added at .5 on the y-axis. A vertical line was then placed
at the intersection of the ogival curve and horizontal line. Where the horizontal line fell on the xaxis was determined to be the estimated threshold. See Figure 1.1 for the graphical
representation. Logistic regression was also used to assess the significance of variables in
predicting KD.
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CHAPTER IV
RESULTS

Group Comparisons
Although there was not a control for every KD participant, there was no significant
difference in ages between the two groups (t(11) = -.328, p = .749). Table 3.1 below shows the
group means for age as well as provides a comparison of genders and ethnicities. Table 3.2
shows group means and standard deviations for each of the olfactory measures excluding DTs.
Table 3.3 illustrates the differences between KD and controls in mean thresholds for each
odorant.

Table 3.1

Comparative Means of Age and Percentage of Demographics between KD and
Control Subjects
Standard Deviations are in parentheses

Group

Age

Males

Females

Caucasian

African
American

Kidney
Disease

56.2
(11.9)

87.5%

12.5%

25.0%

75.0%

No Kidney
Disease

54.4
(11.8)

80.0%

20.0%

80.0%

20.0%
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Olfactory Identifications
The first hypothesis was that KD participants would have lower OI scores compared to
the controls. The hypothesis was not supported (t (11) = 1.395, p = .191). However, average OI
scores for KD participants were lower compared to the controls. See Table 3.2.
Detection Thresholds
The second hypothesis was not supported either. Results for all odorants indicate that
none of the thresholds are significantly higher than the controls. The corresponding results for
Vanillin, Pinene, Ethanol, Banana, and P-Cresol are t (7) = -.243., p = .815, t (6) = -.919, p =
.394, t (7) = -.891, p = .403, t (8) = -.589, p = .572, and t (3) = -.769, p = .498, respectively.
Although the results showed no significant differences between KD and control DTs, the KD
thresholds were higher for all odorants.

Sensitivity
Sensitivity was hypothesized to be lower for KD participants, indicating that they would
have a harder time distinguishing odorants from blanks compared to the controls. Similar to the
analysis for the first hypothesis, the t test again did not reach significance (t (9) = 1.239, p =
.247) despite the fact that sensitivity scores were lower than the controls (with the exception of
vanilla). Further group comparisons were made for each odorant sensitivity, but nothing
significant was found, although sensitivity of P-Cresol approached significantly lower scores for
KD participants (t (9) = 2.225, p =.053).
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Table 3.2

Comparative Means of OI and Sensitivity between KD and Control Subjects
Standard Deviations are in parentheses

Group

OI

Overall
A’’

Vanillin
A’’

Pinene
A’’

Ethanol
A’’

Banana
A’’

P-Cresol
A’’

Kidney
Disease

.70
(.18)

.67
(.08)

.77
(.06)

.57
(.21)

.53
(.15)

.75
(.10)

.61
(.21)

No
Kidney
Disease

.82
(.12)

.74
(.11)

.73
(.18)

.70
(.10)

.66
(.15)

.81
(.07)

.84
(.06)

Table 3.3

Comparative Means of DT for Each Odorant between KD and Control Subjects
Concentration Ranges in parts per million are below odorant name. Standard
Deviations are in parentheses

Group

Vanillin
1.95-500.00

Pinene
7.81-2000.00

Ethanol
3.91-1000.00

Banana
.48-125.00

P-Cresol
.03-8.00

Kidney
Disease

51.56
(43.72)

1273.27
(2102.58)

1245.60
(2084.01)

10.29
(21.03)

3.16
(5.21)

No Kidney
Disease

41.24
(82.49)

282.52
(482.23)

279.07
(558.15)

2.86
(2.50)

0.17
(0.18)

Prediction of Kidney Disease

None of the measures were significant predictors, nor were any combinations of olfactory
measures and/or disorders.
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CHAPTER V
DISCUSSION AND CONCLUSION

Implications of Results
None of the hypotheses were supported by the data analyses. With the exception of
sensitivity to Vanillin, the KD participants performed worse than the controls on all olfactory
measures. Although the prior evidence supported an olfactory deficit in identification abilities
(Corwin, 1989; Raff et al., 2008), the current statistical analyses did not reach significance. The
results from this study do not necessarily mean that these previous studies are not supported, but
instead suggest deficiencies in the current procedure.
The main factor affecting the results is the amount of variance in each olfactory measure.
The only way for the variance in the data to be reduced is by including more participants.
Additionally, there are still too few participants for a representative sample of the population as
whole. Tables 3.1 and 3.2 indicate that this is especially true for DTs; the standard deviations
actually exceed the means and far surpass the differences between the groups. Once enough
participants have been added to generate a high enough statistical power, it may be possible to
see the trends of poorer performance become significant differences.
Even though there was no significant difference in DTs between the two groups, there too
appears a trend of poorer performance on this task. Every single odorant used indicated higher
thresholds for the KD participants. Further analyses showed an interesting factor affecting
performance for both KD and controls. The factors distorting the results are both a floor and
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ceiling effect. This effect is seen separately for the different groups. Control performance
appears to be influenced by a floor effect, while the KD participants are affected by a ceiling
effect. It was discovered that on average, there was not a stimulus with a low enough
concentration to be undetectable for the controls. These floor effects were present for the
controls on Vanillin and Ethanol. Figures 4.1 and 4.2 are graphs that show the relationship of the
average predicted probabilities for each group based on the concentration.
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Figure 4.1

Predicted Probability Curve of Vanillin by Group with Evidence of a Floor Effect
in Control Groups
The horizontal scale is graphed using a logarithmic scale to avoid skewness. Each point on the
graph represents the probability of that concentration being detected with an ogival curve added
for each group. The horizontal line depicts where the probability of .5 would intersect the
probability curve. The corresponding concentration at the intersection of the horizontal line and
probability curve is the estimated threshold. The floor effect is present for the controls given the
predicted probability never drops below .5.
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Figure 4.2

Predicted Probability Curve of Vanillin by Group with Evidence of a Floor Effect
in Control Groups
The horizontal scale is graphed using a logarithmic scale to avoid skewness. Each point on the
graph represents the probability of that concentration being detected with an ogival curve added
for each group. The horizontal line depicts where the probability of .5 would intersect the
probability curve. The corresponding concentration at the intersection of the horizontal line and
probability curve is the estimated threshold. The floor effect is present for the controls given the
predicted probability never drops below .5.

On the other end of the spectrum, there was no concentration strong enough for KD
participants to detect on average. For example, Table 3.2 in the previous section shows the
average threshold for Ethanol higher than the range that was tested. This occurred as a result of
three separate KD participants having their threshold calculated by extrapolating the graph
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beyond the thresholds measured. That is, the predicted probabilities never cross the .5 probability
line for the range of concentrations tested, indicating the presence of a ceiling effect. For those
three participants, this effect occurred on every odorant except Banana.
Despite not having a concentration low enough to measure thresholds for the controls
(thus giving them a threshold concentration of .0) and not having concentrations high enough for
KD participant to detect, there was still no significant difference between groups for these
thresholds. Variance in the thresholds as a result of the small sample size may also be preventing
any significant results from occurring.
As a result of the small sample size, the inferential statistics may not be the best tool to
use assessing the different in DTs between diseases. The following graphs (Figures 4.3 – 4.5)
show the average predicted probability curves for all participants by odorant.
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Figure 4.3

Predicted Probability Curve of Pinene by Group
The horizontal scale is graphed using a logarithmic scale to avoid skewness. Each point on the
graph represents the probability of that concentration being detected with an ogival curve added
for each group. The horizontal line depicts where the probability of .5 would intersect the
probability curve. The corresponding concentration at the intersection of the horizontal line and
probability curve is the estimated threshold.
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Figure 4.4

Predicted Probability Curve of Banana by Group
The horizontal scale is graphed using a logarithmic scale to avoid skewness. Each point on the
graph represents the probability of that concentration being detected with an ogival curve added
for each group. The horizontal line depicts where the probability of .5 would intersect the
probability curve. The corresponding concentration at the intersection of the horizontal line and
probability curve is the estimated threshold.
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Figure 4.5

Predicted Probability Curve of p-Cresol by Group
The horizontal scale is graphed using a logarithmic scale to avoid skewness. Each point on the
graph represents the probability of that concentration being detected with an ogival curve added
for each group. The horizontal line depicts where the probability of .5 would intersect the
probability curve. The corresponding concentration at the intersection of the horizontal line and
probability curve is the estimated threshold.

As seen in the above figures (Figures 4.1 – 4.5), there appears to be performance
differences based on odorant. It appears that there are very little differences in thresholds for KD
participants compared to the controls in Pinene and Banana. However, there are large differences
for the odorants Vanillin and Ethanol. The WUTC did not have a concentration low enough for
the controls to detect on either odorant. Additionally, the WUTC did not contain a concentration
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high enough for KD participants to detect. While no floor or ceiling effect was found for pCresol, the comparison of probability curves does appear to show poorer detection abilities for
KD participants. This difference may also not be statistically significant as a result of the
variability in the data. However, if significance is attained through a larger sample size, the
decrease in DT for P-Cresol may be a result of some biological mechanism used in olfaction
being blocked from the buildup of uremic toxins found in KD (McKinney, 2013) and may
explain why the differences in sensitivity of P-Cresol were so close to significant in the small
sample size. Another explanation for this difference in sensitivity may be a result of the KD
participants being habituated to the odorant. Voss et al. (2005) found that KD patients do not
smell their uremic odorant and their sweat contained high levels of uremic concentrations.

Limitations
As already discussed, the major limitation to the study was sample size. The criterion to
meet in order to be eligible is a very long and specific list (See Appendix A for full list). This
also made it very difficult for the recruitment of controls. Since controls had to be age and
gender matched, recruitment could not be started until KD participants completed their
participation. Further complicating this limitation was a result of having to omit participants
from the already small dataset as a result of test performance. As stated in the introduction, any
value of A’ ≤ .5 is due to an error in response confusion. Two individuals, one in each group,
were removed from the analyses as a result of small A’ values. Their A’ values were indicative
that these participants were guessing through the entire testing procedure. The guessing may
have resulted from a total lack of olfactory ability.
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B coefficients were obtained for every threshold analysis. Some coefficients were
negative, indicating a decrease in predicted probability for detecting odorants as the
concentrations increased. Anyone with an estimation of threshold with a negative B coefficient
was not included in the analyses. The negative coefficients can actually be used for
determinations of response confusion or possible guessing for participants. Surprisingly, this was
only observed in the KD participants. No individual threshold was excluded from the controls as
a result of response confusion. Given that response confusion was only found in KD participants,
it may be indicative of an olfactory deficit.
However, there were a number of thresholds that were not able to be computed for the
controls. These thresholds could not be obtained as a result of responding yes to every stimulus
for an odorant. The logistic regression analysis will not compute predicted probabilities without
the dependent variable assuming exactly two variables. This issue was only seen in the controls.
This could be a result of response bias. Controls did have a higher response bias, indicating a
higher tendency to say yes compared to the KD participants (B’’ = .194, B’’ = -.346,
respectively). The non-significant difference in response bias could be the result of the small
sample size, but it is more likely a result from the ranges used on the WUTC.
Another possible issue resulting from the small sample size is reliability. While Tewalt
(2013) found reliability measures of > .8, the highest reliability observed in the present study was
K = .644 (See table 4.1 for all observed reliability measures for each odorant). The reliability
coefficient used was K to check for agreement in detection or no detection from the first
presentation of a stimulus to its second presentation. Scores can range from -1 (no agreement) to
+1 (high agreement).
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Table 4.1

Observed Reliability Coefficients of the WUTC

Odorant

Overall

KD

Controls

Vanillin

.592

.581

.573

Pinene

.501

.335

.644

Ethanol

.449

.362

.429

Banana

.550

.524

.493

p-Cresol

.535

.377

.552

A statistically significant difference may not have been found as a result of the WUTC
design. Although the WUTC includes the middle concentration reflective of the normative data
on each odorant’s threshold (Tewalt, 2013), the range may have been too restricted for the
samples or populations being tested. The design of the test is restricting the range of sensitivity
in that only half of the odorant containing stimuli is supposed to be detected. This restricted
range may have also been a major cause in creating the ceiling and floor effects observed in the
participants.

Direction of Future Research
The present study is a part of a much larger clinical drug trial that is still ongoing. The
continuation of the study should alleviate the small sample size and reduce the variance.
Olfactory measures may start to differentiate between KD participants and controls. Once the
variance issue has been resolved, the analyses may become significant, given the trend of poorer
olfactory performance in the KD participants. The larger study of which this study was a subset
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of is also assessing the effectiveness of a drug supplementation which could be used to examine
possible treatment effects like those seen in Landis et al. (2011) and Griep et al. (1997).
Adjusting the range of the odorants used in the WUTC is also necessary to analyze
thresholds in both KD and control subjects. Extending the range of the concentrations may
alleviate the presence of the ceiling and floor effects. One recommendation is to exclude two of
the odorants currently in the WUTC. No ceiling or floor effects were found for Pinene or
Banana, nor was there any indication of an obvious difference in probability curves. By
eliminating these two odorants, the ranges can be extended three concentrations in each direction
without adding to the length of the test. By extending the range and increasing the sample size, it
may be possible to predict KD based on olfactory performance.
In addition to extending the ranges of concentrations in the WUTC, there should be a
standardization of odorants used in testing olfactory performance in the KD population. Table
4.1 shows the results of previous studies and the odorants that were used when examining
olfactory abilities in the KD population.
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Table 4.2

Comparison of Results from Previous Olfactory Assessments of KD when
Compared to Controls
OI tests used and the odorant(s) used in the study are reported in the parentheses.
Study

Olfactory Identification

Detection Thresholds

The Present Study

Non-significantly Lower
(UPSIT)

Non-Significantly Higher
(Vanillin, Pinene, Ethanol,
Isoamyl Acetate, p-Cresol)

Landis et al. (2011)

Significantly Lower (Sniffin’
Sticks)

Frasnelli et al. (2002)

Significantly Lower (Sniffin’
Sticks)

Normal (n-Butanol)

Griep et al. (1997)

-

Significantly Higher (Isoamyl
Acetate)

Korytowska and Szmeja
(1993)

Significantly Lower (Coffee
and Lemon)

Normal (Coffee, Lemon Oil)

Normal (n-Butanol)
Elevated (Acetic Acid)

Only two odorants were used in more than one study, n-Butanol and Isoamyl Acetate,
both of which have a banana smell. The reason the mixed results have been found in the DT
literature may be a result of not using an odorant or odorants that are affected by the symptoms
of the disease, like levels of uremic toxins in the blood.
Given the differences found with P-Cresol, both in sensitivity and thresholds, blood
analyses should be done to determine if there is a relationship between P-Cresol blood levels and
olfactory performance. McKinney (2013) found there was no P-Cresol in healthy individuals,
which means P-Cresol may be the cause for the olfactory deficits. If there is an indication of a
negative relationship, then further analyses can assess why P-Cresol may be hindering olfactory
performance.
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Conclusion
There has been conflicting data in regards to olfactory performance in KD. While there is
a trend for deficits in OI, the results for DT are inconsistent. The prior results indicate poorer
performance, no difference in performance, or varied performance between odorants when
compared to healthy individuals. Further complicating the relationship of olfaction and KD is the
increased prevalence of sleep disorders and depression. Both of these disorders have also been
linked to declines in olfactory performance.
Although there were no statistically significant differences found in olfactory abilities
between KD participants and controls, there does appear to be a trend for poorer olfactory
abilities. The difference observed may not have been found significant as a result of the small
sample size or as a result of the floor and ceiling effects found. Furthermore, the small sample
size and large amount of variance may also have prevented any significant predictors of olfactory
abilities and KD from being found.
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APPENDIX A
INCLUSION AND EXCLUSION CRITERIA FOR KIDNEY DISEASE
PARTICIPANTS
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INCLUSION/EXCLUSION CRITERIA:

Inclusion Criteria:
1)
2)
3)
4)

Patient age > 18 and <85 years of age
Patients with CKD or ESRD with eGFR < 30 mls/min
If receiving hemodialysis, patients must be on treatment > 3 months
Normal healthy controls must be without a known history of CKD and be willing to
have formal PSG test and plasma melatonin measurements

Exclusion Criteria:
1) Patients receiving outpatient hemodialysis for < 3 months
2) Patients with estimated GFR by Cockcroft Gault > 30 mls/min
3) Patients receiving beta blocker therapy within one month of randomization
4) Patients receiving Nifedipine therapy within one month randomization
5) Patients on peritoneal dialysis
6) Patient with chronic home oxygen supplementation
7) Patients receiving chronic home CPAP therapy
8) Patients actively receiving outpatient sleep medications
9) Patients with diabetic gastroparesis unresponsive to medication
10) Patients with known pregnancy or unwilling to use contraception during the course of
the study
11) Patients with a functioning renal allograft
12) Patient currently receiving long-term immunosuppressive therapy. Patients receiving
low dose prednisone (10mg or less per day) will not be excluded from this trial
13) Unable to give informed consent
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APPENDIX B
DEMOGRAPHIC QUESTIONNAIRE FOR CONTROL
SUBJECTS

50

Age (in years): _________
Gender (circle one);

Male

Female

If female, please answer the questions located on the next page. ***
Ethnicity (circle one):

Caucasian

Bi-Racial

African American

Asian American

Hispanic

Other (please indicate): _______________________________

Do you currently smoke (circle one):

Yes

No

Yes

No

If yes; How many cigarettes per day?_____; Cigars per day?____
What type of cigarettes do you smoke? __________________________
How many years have you smoked? ______________
If not currently smoking, have you ever smoked? (Circle one):
If yes, how long ago did you stop?_______
How many cigarettes did you smoke per day?_____; Cigars per day?_____
Did your ability to smell change after you stopped smoking? (Circle one):

Yes

No

If yes; How?
_____________________________________________________________________________________
_____________________________________________________________________________________

What is your occupation: ____________________________________________________
Highest grade completed? (Circle only one number):
6

7

8

9

10

11

12 College 1

2

3

4

5

+

Please indicate if you have had past history of the following medical Illnesses. (Circle Yes or No):
High blood pressure

Yes

No

Diabetes

Yes

No

Arthritis

Yes

No

Heart disease

Yes

No

Thyroid disorder

Yes

No

Headaches

Yes

No

Lung trouble

Yes

No

Gout

Yes

No

Epilepsy

Yes

No

Circulation problems

Yes

No

Broken nose

Yes

No

Anemia

Yes

No

Strokes

Yes

No

Eye problems

Yes

No

Asthma

Yes

No

Cancer

Yes

No
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Please indicate if you have had past history of the following medical Illnesses. (Circle Yes or No):
Hepatitis

Yes

No

Ulcer

Yes

No

Hiatal hernia

Yes

No

Kidney disease

Yes

No

Pelvic disease

Yes

No

Skin disease

Yes

No

Prostate problems

Yes

No

Infections

Yes

No

Bleeding/clotting disorder

Yes

No

HIV

Yes

No

TB

Yes

No

Neurological disease

Yes

No

Deviated septum

Yes

No

Sinus problems

Yes

No

Concussion/head trauma

Yes

No

Medical allergies

Yes

No

Food allergies

Yes

No

Seasonal allergies

Yes

No

Other: _______________________________________________________________________________
Please indicate if you are currently taking any of the following types of medications. (Circle Yes or
No):
Antibiotics

Yes

No

Antidepressants

Yes

No

Hormone replacements

Yes

No

Antihistamines

Yes

No

Antihypertensive

Yes

No

Antianxiety

Yes

No

Lithium

Yes

No

Anti-inflammatory†

Yes

No

Yes

No

†

Including ibuprofen

Antineoplastic††
††

Examples of Antineoplastics are Elspar (asparaginase), Alkeran (melphalan), floxuridine,
lomustine, procarbazine, thioguanine, thiotepa
Stimulant medications†††
†††

Yes

No

Examples of Stimulant medications are Adderall and Vyvanse

Have you ever been diagnosed with Sleep Apnea? (Circle one):

Yes

No

***Females (optional, But VERY BENEFICIAL to answering research questions)
If FEMALE; Are you currently on your menstrual cycle? (Circle one):

Yes

No

If FEMALE; Are you currently pregnant? (Circle one):

Yes

No

If FEMALE; Are you in menopause or post menopause? (Circle one):

Yes

No

52

APPENDIX C
UNIVERSITY OF PENNSYLVANIA SMELL
IDENTIFICATION KEY
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UPSIT Key
1. B – Pizza
2. B – Bubble Gum
3. D – Menthol
4. D – Cherry
5. C – Motor Oil
6. B – Mint
7. A – Banana
8. B – Clove
9. C – Leather
10. B – Coconut
11. C – Onion
12. B – Fruit Punch
13. A – Licorice
14. D – Cheddar Cheese
15. B – Cinnamon
16. D – Gasoline
17. A – Strawberry
18. A – Cedar
19. B – Chocolate
20. C – Gingerbread

21. A – Lilac
22. A – Turpentine
23. B – Peach
24. A – Root Beer
25. B – Dill Pickle
26. C – Pineapple
27. D – Lime
28. B – Orange
29. B – Wintergreen
30. D – Watermelon
31. D – Paint Thinner
32. C – Grass
33. C – Smoke
34. A – Pine
35. D – Grape
36. D – Lemon
37. A – Soap
38. D – Natural Gas
39. B – Rose
40. A – Peanut
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APPENDIX D
WUTC EXAMPLE SEQUENCE SHEET
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Melatonin Threshold
Sequence/Response
Sheet

Name:___________________________

Admin: ______________________
Sequence

6
39
43
50
35
48
10
31
44
34
5
41
16
22
51
52
47
40
46
11
32
42
36
20
22
53
25
25
14
1
1

Remaining

100

90

80

Answer

Date: ____________

Record:
____________________
yes=1, no=0

First time
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
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Second time
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]

49
6
48
11
52
51
54
20
29
45
26
26
10
18
4
13
19
54
7
15
35
53
2
9
15
30
2
33
21
12
4
12
38
27
24
23
9
38
41

70

60

[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
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50

40

57

[86]
[87]
[88]
[89]
[90]
[91]
[92]
[93]
[94]
[95]
[96]
[97]
[98]
[99]
[100]
[101]
[102]
[103]
[104]
[105]
[106]
[107]
[108]

3
8
39
28
45
36
19
7
3
44
50
28
24
33
5
42
27
31
29
14
43
23
13
16
17
17
49
30
40
8
18
37
46
32
21
47
34
37

30

20

10
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APPENDIX E
CENTER FOR EPIDEMIOLOGIC STUDIES
DEPRESSION – REVISED SCALE
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Place a check mark or “X” in the appropriate box. Only select one for each question.
Last Week
Below is a list of the ways you might
have felt or behaved. Please check
the boxes to tell me how often you
have felt this way in the past week or
so.

Not at all
or Less
than 1
day

1-2 days

1) My appetite was poor.
2) I could not shake the blues.
3) I had trouble keeping my
mind on what I was doing.
4) I felt depressed.
5) My sleep was restless.
6) I felt sad.
7) I could not get going.
8) Nothing made me happy.
9) I felt like a bad person.
10) I lost interest in my usual
activities.
11) I slept much more than
usual.
12) I felt that I was moving too
slowly.
13) I felt fidgety.
14) I wished I were dead.
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3-4 days

5-7 days

Nearly
every
day for 2
weeks

Place a check mark or “X” in the appropriate box. Only select one for each question.
Last Week
Below is a list of the ways you might
have felt or behaved. Please check
the boxes to tell me how often you
have felt this way in the past week or
so.

Not at all
or Less
than 1
day

1-2 days

15) I wanted to hurt myself.
16) I was tired all the time.
17) I did not like myself.
18) I lost a lot of weight
without trying to.
19) I had a lot of trouble
getting to sleep.
20) I could not focus on the
important things.
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3-4 days

5-7 days

Nearly
every
day for 2
weeks

APPENDIX F
PITTSBURG SLEEP QUALITY INDEX
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During the past month,
1.
2.
3.
4.

When have you usually gone to bed (what time)? _________________
How long (in minutes) has it taken you to fall asleep each night? ________________
When have you usually gotten up in the morning? ____________________
How many hours of actual sleep do you get at night? (This may be different than the number
of hours you spend in bed) _________________

5. During the past month, how often have you had
trouble sleeping because you…

Not
during
the past
month

Less
than
once a
week

Once or
twice a
week

Three or
more
time a
week

Very
Good

Fairly
Good

Fairly
Bad

Very
Bad

a. Cannot get to sleep within 30 minutes
b. Wake up in the middle of the night or early
morning
c. Have to get up to use the bathroom
d. Cannot breathe comfortably
e. Cough or snore loud
f. Feel too cold
g. Feel too hot
h. Have bad dreams
i. Have pain
j. Other reason(s), please describe, including how
often you have trouble sleeping because of this
reason(s):
6. During the past month, how often have you taken
medicine (prescribed or “over the counter”) to help
you sleep?
7. During the past month, how often have you had
trouble staying awake while driving, eating meals, or
engaging in social activity
8. During the past month, how much of a problem has it
been for you to keep your enthusiasm to get things
done?

9. During the past month, how would you rate your
sleep quality overall?
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IRB APPROVAL LETTER FOR KIDNEY DISEASE PATIENTS
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MEMORANDUM

TO:

Dr. Nicky Ozbek
Dr. James Tumlin

IRB # 12-196

FROM:

Lindsay Pardue, Director of Research Integrity
Dr Bart Weathington, IRB Committee Chair

DATE:

November 28, 2012

SUBJECT:

IRB Application # 12-196: Olfactory Sensitivity and Depression in Dialysis Patients

The IRB Committee Chair has reviewed and approved your application and assigned you the IRB number
listed above. You must include the following approval statement on research materials seen by
participants and used in research reports:
The Institutional Review Board of the University of Tennessee at Chattanooga (FWA00004149) has
approved this research project # 12-196.
Since your project has been deemed exempt, there is no further action needed on this proposal unless
there is a significant change in the project that would require a new review. Changes that affect risk to
human subjects would necessitate a new application to the IRB committee immediately.
Please remember to contact the IRB Committee immediately and submit a new project proposal for
review if significant changes occur in your research design or in any instruments used in conducting the
study. You should also contact the IRB Committee immediately if you encounter any adverse effects
during your project that pose a risk to your subjects.
For any additional information, please consult our web page http://www.utc.edu/irb or email us at:
instrb@utc.edu .
Best wishes for a successful research project.
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IRB APPROVAL LETTER FOR CONTROL PARTICIPANTS
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APPENDIX I
INFORMED CONSENT FOR HEALTHY CONTROLS
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Informed Consent Form
While we hope that you will complete the attached study, your participation is voluntary. You
may elect not to participate at any time. In addition, if you do not feel comfortable answering any
of the questions you may leave that question blank and continue with the rest of the study. The
information you provide will be anonymous and we do not ask you to identify yourself in any
way. Emotional and/or Psychological Stress, Boredom, Nasal Dryness, and/or an Allergic
Reaction are possible risks associated with your participation in this project. You will not receive
any direct benefit from participating in the study.
This first part of the study will ask you to respond to questions about sleeping, general health,
and recent feelings or behaviors. The second part of the study will ask you to identify smells
located on scratch and sniff booklets. The third part will ask you to respond whether or not you
detected an odor in a tube. The last thing the study asks you to do is fill out a demographic page.
The demographic information will ask about age, gender, ethnicity, occupation, education,
smoking habits, and specific medical illnesses and medications. These questions will help us to
interpret the results of the rest of the study.
The researcher will ask you for any allergies you may have. Depending on your allergies, you
may be excluded from participating. If an allergic reaction does occur, you will be taken to the
University Health Services for an allergy shot.
Some questions may cause emotional or psychological distress. If you experience either type of
distress, please contact the University Counseling Center. They can be reached by phone or on
site during walk-in hours.
Phone: 423-425-4438
Walk-in Hours: Monday – Friday, 9:00am-11:30am and 1:00pm-3:30pm
We expect that it will take approximately 1 hour to participate in this study.
Remember, this is an anonymous survey, so please do not write your name anywhere other than
this page. You may also request a copy of this form for your records.
Who to Contact
If you have any questions or would like to obtain a report of this research study when the results
have been completed, please contact Dr. Nicky Ozbek (423-425-4262), Department of
Psychology, University of Tennessee at Chattanooga. This survey is being conducted as part of
a Graduate Thesis. This project meets the requirements for approval by the UTC IRB and
contact can be made to the UTC IRB through Director Lindsay Pardue (423-425-4443) and Chair
Dr. Bart Weathington (423-425-4289).
By signing the consent, you are indicating that you are at least 18 years of age.
Thank you for participating in our research!
Name (Print) _____________________________________________ Date________________

Signature ________________________________________________ Date________________
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